Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26224766.
- Also identified by DOI 10.1093/cid/civ484.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The in vitro hollow fiber system model has been qualified by the European Medicines Agency as a methodology for use in support of selection and development of antituberculosis regimens. More data are expected to be generated in the future to further characterize its value.
Medical subject headings
- Antitubercular Agents
- Drug Discovery
- Drug Evaluation, Preclinical
- Mycobacterium tuberculosis
- Tuberculosis